#USA #biotech #Longmont #Cambrex #Eli Lilly

Cambrex Teams Up with Eli Lilly for Advancing Biotech Manufacturing

In a groundbreaking development within the biotech industry, Cambrex, a renowned global contract development and manufacturing organization (CDMO), has formalized a strategic alliance with Eli Lilly and Company. This partnership aims to accelerate clinical development capabilities specifically tailored for Lilly’s biotech collaborators, significantly enhancing the product development process for emerging therapies.

This agreement, announced on December 5, 2024, marks a notable collaboration between two industry leaders. Cambrex will work alongside Lilly’s innovative unit, Catalyze360-ExploRD, which focuses on external collaborations to expedite product development in the biotech sphere. Through this partnership, Cambrex will provide a holistic suite of services, including drug substance development, product formulation, and analytical services designed to streamline the pathway from concept to clinic for biotech innovators.

Brandon Fincher, President of Early Stage Development Testing at Cambrex, expressed enthusiasm about this new partnership, stating, "We are excited to support Lilly's mission to enable external biotech collaborators to expedite their product development." He further highlighted that Cambrex's facilities in Longmont, Colorado, are equipped to address all necessary stages of early drug development with agility, precision, and scientific excellence.

The Longmont facility is particularly well-suited for developing investigational new drugs, offering comprehensive services from process development and drug substance manufacturing to formulation and drug product manufacturing. Cambrex is capable of both non-GMP and cGMP production, ensuring that all partners receive the highest quality support tailored to their specific needs. In addition, the Longmont site provides essential analytical development and cGMP testing support for projects.

Lilly Catalyze360 is designed to foster scientific advancements and nurture emerging therapies through its three primary segments: Lilly Ventures, Lilly Gateway Labs, and Lilly ExploRD. Cambrex's collaboration with the ExploRD unit adds a layer of expertise and support, enhancing the value brought to biotech collaborators. This partnership effectively combines Cambrex’s extensive R&D background and manufacturing capability with Lilly’s validation and market insight, creating a synergistic environment for advancing drug development.

With over 40 years of experience, Cambrex has established itself as a major player in the pharmaceutical manufacturing space, employing around 2,000 professionals who cater to global clients across North America and Europe. Their expertise encompasses a wide range of drug substance technologies, including continuous flow chemistry, solid-state science, and the handling of highly potent APIs, making them an invaluable partner for biotech firms aiming to innovate.

As the demand for new and effective drugs grows, Cambrex and Eli Lilly’s proactive approach to creating a more responsive and efficient development ecosystem will serve not only their immediate goals but also contribute significantly to the broader public health landscape. This strategic partnership is poised to impact the future of biotech product development by providing the necessary resources and expertise to propel groundbreaking therapies into the market.

In summary, Cambrex’s collaboration with Eli Lilly highlights a significant step in the evolution of biotech manufacturing, paving the way for innovative therapies to reach patients faster while ensuring quality and efficacy remain a priority. This agreement is a beacon of hope for smaller biotech companies seeking to make their mark in a competitive industry, granting them access to expansive resources and superior knowledge that could define the next generation of medical advancements.